Clinical Trial Update: Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of Phase 1/Phase 2 clinical trials evaluating CTLA4-IgG4m (RG2077) in patients with systemic lupus erythematosus and lupus …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• CTLA4-IgG4m (RG2077) (CTLA4-IgG4m)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 1, Phase 2 | Status: COMPLETED